CommentGlobal framework on essential health R&D
References (13)
- et al.
Drug development output from 1975 to 1996: what output for tropical diseases?
Int J Infect Dis
(1999) - et al.
Drug development for neglected diseases
Lancet
(2002) Global framework on essential health research and development
- et al.
Access to essential drugs: a lost battle?
JAMA
(1999) 30 ans de résultats de la recherche pharmaceutique dans le monde (1975–2004)
Dutch registration for artemotil injections
There are more references available in the full text version of this article.
Cited by (146)
Selected Aspects of the Analytical and Pharmaceutical Profiles of Nifurtimox
2023, Journal of Pharmaceutical SciencesExploration of biological potency of carboxylic acid derivatives: Designing, synthesis, characterizations and molecular docking study
2020, Journal of Molecular StructureSynthesis of heteroleptic pentavalent antimonials bearing heterocyclic cinnamate moieties and their biological studies
2018, Inorganica Chimica ActaCitation Excerpt :Leishmaniasis is considered by – WHO as one of the six epidemic diseases worldwide with limited number of available drugs. So, the synthesis of new drugs for the neglected disease has become a global concern [6]. In 1940s, trivalent antimonials were replaced by the two more effective pentavalent antimonials i.e., sodium stibogluconate (Pentostam®) and meglumine antimoniate (Glucantime®).
Copyright © 2006 Elsevier Ltd. All rights reserved.